battled wohl gerade mit TORL 1-23, der sich auch gegen Claudin6 richtet...
Habe jetzt KI gefragt, welche Daten more promising sind, wären sonst 5 Bilder gewesen:
Both BioNTech’s BNT211 and TORL Biotherapeutics’ anti-Claudin6 ADC (TORL-1-23) were featured at ESMO 2024, each showcasing promising results in their respective trials targeting Claudin-6 (CLDN6), a key marker in various solid tumors.
1.§BNT211 (BioNTech): This is a CAR-T cell therapy aimed at CLDN6-expressing tumors, enhanced by an mRNA-based CARVac vaccine. In its Phase 1/2 trials, BNT211 showed an overall response rate (ORR) of 45% in solid tumors like ovarian and testicular cancer, with a disease control rate (DCR) of 74%. Higher doses combined with the CARVac vaccine demonstrated better efficacy, including partial responses in 59% of patients at dose level 2, and durable responses in some cases 2.§TORL-1-23 (TORL Biotherapeutics): TORL’s ADC also targets CLDN6 and has shown encouraging early results in heavily pretreated ovarian cancer patients. While dose escalation is ongoing, the initial data revealed partial responses in about 33% of patients with CLDN6+ ovarian cancer, particularly at the highest dose level (2.4 mg/kg), with good tolerability and no dose-limiting toxicities reported so far
Comparing both, BNT211 seems to have slightly more advanced and promising data in terms of durability and deeper responses, especially with the CARVac combination in solid tumors like testicular cancer. However, TORL-1-23’s focus on ovarian cancer and its tolerability also show potential, particularly for this challenging cancer subtype. Further data from ongoing trials will provide more clarity.
|